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Kevin Burgess2 & Hong Boon Lee3
Tropomyosin receptor kinase C (TrkC) targeted ligand-photosensitizer construct, IYIY-diiodo-boron-
dipyrromethene (IYIY-I2-BODIPY) and its scrambled counterpart YIYI-I2-BODIPY have been prepared. 
IYIY-I2-BODIPY binds TrkC similar to neurotrophin-3 (NT-3), and NT-3 has been reported to modulate 
immune responses. Moreover, it could be shown that photodynamic therapy (PDT) elevates antitumor 
immune responses. This prompted us to investigate the immunological impacts mediated by IYIY-I2-
BODIPY in pre- and post-PDT conditions. We demonstrated that IYIY-I2-BODIPY (strong response) and 
YIYI-I2-BODIPY (weak response) at 10 mg/kg, but not I2-BODIPY control, increased the levels of IL-2, 
IL-4, IL-6 and IL-17, but decreased the levels of systemic immunoregulatory mediators TGF-β, myeloid-
derived suppressor cells and regulatory T-cells. Only IYIY-I2-BODIPY enhanced the IFN-γ+ and IL-17+ 
T-lymphocytes, and delayed tumor growth (~20% smaller size) in mice when administrated daily for 5 
days. All those effects were observed without irradiation; when irradiated (520 nm, 100 J/cm2, 160 mW/
cm2) to produce PDT effects (drug-light interval 1 h), IYIY-I2-BODIPY induced stronger responses. 
Moreover, photoirradiated IYIY-I2-BODIPY treated mice had high levels of effector T-cells compared 
to controls. Adoptive transfer of immune cells from IYIY-I2-BODIPY-treated survivor mice that were 
photoirradiated gave significantly delayed tumor growth (~40–50% smaller size) in recipient mice. 
IYIY-I2-BODIPY alone and in combination with PDT modulates the immune response in such a way that 
tumor growth is suppressed. Unlike immunosuppressive conventional chemotherapy, IYIY-I2-BODIPY 
can act as an immune-stimulatory chemotherapeutic agent with potential applications in clinical cancer 
treatment.
Conventional cancer chemotherapy is frequently associated with non-selective toxicity, treatment resistance and 
immune response silencing1,2. These restrictions generally lessen the effectiveness of chemotherapy. Actively 
targeted cancer therapies guide the agents to biomolecules (proteins, sugar or lipids) overexpressed on the cell 
surface, thus increasing their cellular uptake through the endocytic internalization3. Extensive studies have been 
carried out to design drug conjugates that selectively bind receptors (generally survival or metastasis biomarker in 
cancer) such as biotin, folate, sigma-2, carbonic anhydrase IX, glucose receptors and others4,5. The delivery agents 
1Department of Pharmacology, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia. 
2Department of Chemistry, Texas A & M University, Box 30012, College Station, Texas 77842, United States. 
3Department of Pharmacy, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia. 
Correspondence and requests for materials should be addressed to C.S.K. (email: cskue85@yahoo.com) or L.V.K. 
(email: lvkiew@ummc.edu.my) or H.B.L. (email: hongboonlee@um.edu.my)
received: 10 May 2016
accepted: 26 October 2016
Published: 17 November 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:37209 | DOI: 10.1038/srep37209
used are generally natural ligands such as hormones, glucose derivatives, vitamins or synthetic small molecules 
ligands that possess similar biological functions6.
Our studies focus on the tropomyosin receptor kinase (Trk). These receptors are found in neurons where they 
regulate the neuronal cell survival and growth, proliferation, differentiation and synaptic strength and plasticity7, 
but also in neuroblastoma8,9, glioblastoma10, thyroid cancer11, melanoma12 and breast cancer13 where they impact 
malignancy. The expression and function of Trk subtypes are dependent on the tumor type. In neuroblastoma, 
TrkC expression correlates with good prognosis, but in breast, prostate and pancreatic cancers, the expression 
of the same Trk subtype is associated with cancer progression and metastasis13,14. Furthermore, ligands binding 
Trk receptors activate downstream intracellular signalling pathways that enhance tumor cell mitogenicity and 
survival8,9. Inhibition of Trk signaling significantly reduced tumorigenicity and invasive capability of tumor cells 
in in vivo xenograft models13,15. Several Trk receptors targeted chemotherapeutic drugs which are inhibitors of all 
TrkA/B/C receptors, are currently in clinical trials for treatment of solid tumors16.
Trk receptors and their ligands have been reported to modulate the immune system. The natural ligands of 
Trk receptors, neurotrophins, which include neurotrophin-3/-4 (NT-3/NT-4), brain-derived neurotrophin factor 
(BDNF) and neurotrophin growth factors (NGF), can function as non-cytokine mediators to modulate both 
innate and adaptive immune responses. Such modulations include increasing the pluripotent cytokine interleukin 
(IL)-6 secretion in bone marrow stromal cells17,18. In addition, neurotrophins have been reported to enhance dif-
ferentiation of granulocytes (eg eosinophils, mast cells and basophils) during haematopoeisis19. In T-lymphocytes, 
neurotrophins regulate T cell subtypes balancing upon binding to TrkC expressing T helper (Th) 2 cell by pro-
moting IL-4 release, which in turn blocks Th1 subtype and IFN-γ production20. Other than neurotrophins, TrkC 
was also reported to suppress transforming growth factor (TGF)-β signaling by directly binding to type II TGF-β 
receptor to block the association with type I receptor as well as to reduce TGF-β mediated downstream Smad2/3 
phosphorylation in TrkC expressing cells21. Furthermore, Trk receptors are expressed in small quantities in 
monocytes and lymphocytes. However, despite all the above evidence that links Trk receptors to modulation of 
the immune system, there are currently no reports that explore Trk receptors in the context of possible strategies 
for immune therapy.
Photosensitizers (PS) are agents used in photodynamic therapy (PDT). In anticancer PDT, the adminis-
tered PS is activated upon irradiation to generate singlet oxygen species to kill tumor cells. Diiodo boron dipy-
rromethene (I2-BODIPY) is a synthetic PS that has been reported to have high extinction coefficient and good 
light-to-dark toxicity ratio, fulfilling the criteria of a favorable PS22,23. However, I2-BODIPY has poor localization 
in tumor. Voon et al. has reported the development of nanoparticles-coated I2-BODIPY for passive delivery to 
the tumor region24. For an active targeting approach, we designed a TrkC receptor targeted I2-BODIPY construct, 
consisting of a synthetic TrkC ligand (Isoleucine-Tyrosine-Isoleucine-Tyrosine, IY-IY) conjugated to I2-BODIPY, 
termed as IYIY-I2-BODIPY (Fig. 1a). A scrambled, non-TrkC targeted ligand conjugate YIYI-I2-BODIPY and 
I2-BODIPY were used as controls (Fig. 1b)25,26, with and without light irradiation.
In our previous study6, the IYIY-ligand was found to induce some biological properties that are similar to 
neurotrophin-3, including internalization of the ligand-receptor complex into lysosomes, and transduction of 
signals that regulate neuronal cell survival and differentiation. Moreover, other researchers have shown that the 
resultant tumor lysate post irradiation can stimulate antigen specific immune responses to mediate short-term 
tumor killing and long-term tumor immunity27–29. Based on these and the previously reported immunological 
effects of TrkC and NT-3, we further investigated the systemic immunological impacts seen on the administra-
tion of the IYIY-I2-BODIPY conjugate in a preclinical murine model. Specifically, we examined the systemic 
modulation of cytokine levels, characterization of myeloid innate immune responses and adaptive immune T 
cell subtypes populations upon IYIY-I2-BODIPY administration in the absence of photo-activation (dark). As 
the I2-BODIPY is not active in the dark, studying the IYIY-I2-BODIPY construct in this setting may help to 
elucidate the immune-regulatory function of the IYIY ligand. This may be important, especially for PDT agents 
Figure 1. Structures of the designed conjugates featured in this work. (a) IYIY-I2-BODIPY is TrkC receptor 
targeted conjugate and (b) YIYI-I2-BODIPY is a scrambled control. Red represents the designed peptide-ligand 
portion, black for the linker and green for the parent iodinated BODIPY (I2-BODIPY).
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that have long drug-light interval (DLI) since the ligand in the conjugate may exert its therapeutic effect even 
before photo-activation of the PS. This is the first study on the immunomodulation properties and anti-tumor 
activity of a synthetic TrkC ligand. In addition, combination of the IYIY ligand targeting effect and simultaneous 
photo-activation of the I2-BODIPY component on immune responses was investigated.
Results
IYIY-I2-BODIPY and YIYI-I2-BODIPY conjugates increase pro-inflammatory cytokines IL-2, IL-4, 
IL-6, IL-17 and decrease immunosuppressive cytokine TGF-β in peripheral blood. In the initi-
ation phase of the adaptive immune response, antigen-specific lymphocytes (T and B cells) are activated when 
they are exposed to antigen. Such activation of T-helper (Th) CD4+ lymphocytes causes them to differentiate into 
four different subtypes (Th1, Th2, Th17, regulatory T cells) depending on the availability of the different types of 
differentiation factors (cytokines) in the environment. The differentiated subtypes of T cells then secrete various 
specific cytokines. For instance, Th1 secrete IL-2, IFN-γ , TNF-α , Th2 secrete IL-4, IL-6, IL-10, Th17 secrete IL-17 
and regulatory T cells (Treg) secrete TGF-β . These cytokines stimulate CD8+ T cells such as cytotoxic T lympho-
cytes (CTL), T cytotoxic (Tc)-17 cells to facilitate further adaptive immune responses. The following experiments 
were conducted to examine if IYIY-BODIPY modulates the cytokines secretion.
We first investigated the cytokine levels in TrkC + murine 4T1 breast cancer model13 that has been treated 
with IYIY-I2-BODIPY, YIYI-I2-BODIPY or I2-BODIPY, the latter two as controls. Blood plasma samples were 
collected from 4T1 tumor bearing mice via cardiac puncture at 2 h and 24 h post compound administration with 
no photo-activation (hereafter referred to as dark treatment) to examine early and late immune responses respec-
tively. All treatment groups had significant increased levels of Th1 cytokine IL-2 at 2 h and 24 h (0.7–1.9 pg/mL) 
compared to saline (0–0.3 pg/mL; p < 0.05 for IYIY-I2-BODIPY and YIYI-I2-BODIPY vs saline at 2 h; Fig. 2a). 
Since IL-2 is usually produced to promote activation and proliferation of T cells30, the observed elevation of 
IL-2 suggests that investigated compounds in the dark induced T cell responses. Increases in levels of other Th1 
cytokines such as IFN-γ and TNF-α were hardly significant in all treatment groups compared to the mice treated 
with saline control (Supplementary Figure 1a,b), suggesting that Th1-mediated inflammation was mild.
IL-6 is a set of pluripotent pro-inflammatory cytokines that regulate differentiation and functions of T lympho-
cytes as well as expansion of myeloid cells31,32. The levels of IL-6 were significantly elevated in IYIY-I2-BODIPY 
treated mice (approximately 7.5-, 2.6- and 4.6-fold compared to mice treated with saline control, I2-BODIPY 
and YIYI-I2-BODIPY respectively at 2 h; p < 0.05). The increase of IL-6 level did not persist, as the level at 24 h 
decreased even though it was still significantly higher compared to other groups (Fig. 2b).
Another cytokine, namely IL-4 was measured with 1 to 2.4 pg/mL in all mice treated with the IYIY-I2-BODIPY, 
YIYI-I2-BODIPY and I2-BODIPY at 2 h only compared to mice treated with saline (undetected, Fig. 2c), in a 
non-compound specific manner. At 24 h, IL-4 levels decreased in all the compound treated groups. Levels of the 
Th2 immunosuppressive cytokine IL-10 induced by these compounds were comparable (6–9 pg/mL) in these 
Figure 2. IYIY-I2-BODIPY and YIYI-I2-BODIPY conjugates increase IL-2, IL-6, IL-17 and decrease TGF-β 
cytokine levels. 4T1 tumor bearing mice were randomly divided into four treatment groups (saline, I2-BODIPY, 
YIYI-I2-BODIPY and IYIY-I2-BODIPY) and compounds were administrated via tail vein respectively. Mice 
were then sacrificed at 2 h and 24 h post compound administration. The blood plasma was extracted from these 
mice via cardiac puncture for cytokines analysis. Levels of cytokines (a) IL-2, (b) IL-6, (c) IL-4, (d) IL-17A and 
(e) TGF-β are shown. Data represent mean ± SEM with minimum of four mice per group. *p < 0.05, **p < 0.005 
refers to comparison between I2-BODIPY and conjugates using one-way ANOVA (Dunnett’s test).
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experiments (Supplementary Figure 1c). Together, the data indicate that the Th2 cytokines (IL-4, IL-6) were tran-
siently elevated, whereas the Th1 response were very mild (weak TNF-α at 2 h, no change for IFN-γ ). In addition, 
there was minor increase (1.3-fold) in the level of pro-inflammatory IL-17A which is specifically secreted by 
IL-17+ T cells, only in IYIY-I2-BODIPY treated group at 24 h compared to other treatment and control groups. 
There was no significant change in the IL-17A levels at 2 h post compound administration when compared to 
mice treated with I2-BODIPY (Fig. 2d). Furthermore, levels of immunosuppressive cytokine TGF-β was signif-
icantly suppressed only in IYIY-I2-BODIPY and YIYI-I2-BODIPY treated groups at 2 h (4.0-fold and 3.0-fold 
respectively, Fig. 2e) compared to mice treated with I2-BODIPY.
Based on the non-persistent increases of IL-4 and IL-6, as well as the declining level of IL-2 with time, we 
concluded that ligand-drug conjugate treated mice selectively provoke transient inflammation. Among the 
compounds investigated, IYIY-I2-BODIPY had the highest immune modulation activity. We had previously 
reported that YIYI-I2-BODIPY possessed positive but lower targeting selectivity on TrkC+ cells compared to 
IYIY-I2-BODIPY26. Therefore, it is conceivable that the YIYI ligand could elicit similar but weaker immune 
responses compared to IYIY, as reflected by the levels of IL-2, IL-4 and TGF-β . I2-BODIPY alone in the dark only 
caused mild immune responses albeit with statistical significance in some cases (p < 0.05 for IL-6 at 2 h, IL-4 at 
2 h and 24 h, IL-2 at 24 h, compared to saline). This further indicated that the immunomodulation properties of 
the TrkC ligand-PS conjugate was mainly contributed by the TrkC ligand counterpart. In addition, the data was 
also in agreement with the previous study showing that YIYI-ligand had weak binding affinity on TrkC receptor26.
IYIY-I2-BODIPY and YIYI-I2-BODIPY conjugates reduce populations of immunosuppressive 
cells. Cancer growth is normally accompanied by expansion of a heterogeneous group of immunosuppressive 
cells collectively known as myeloid derived suppressor cells (MDSCs). In particular, the granulocytic-MDSC 
(G-MDSC) subtype promotes tumor relapse by impairing the effectiveness of host immunity through inhibition 
of T-cell activation when primed by the tumor antigen33,34. Cancer growth is also associated with an increase in 
regulatory T cells (Treg) to suppress antitumor T cell responses as a method of escaping immune-surveillance. 
The expansion and differentiation of MDSCs and Treg cells are known to be mainly regulated by cytokines 
IL-631,32 and TGF-β , respectively. Following the increase of IL-6 in IYIY-I2-BODIPY treated mice and decrease of 
TGF-β in both conjugate-treated mice, we sought to investigate changes in G-MDSCs and Treg cell populations 
in these animals.
IYIY-I2-BODIPY treated mice had significant lower level of G-MDSCs (CD11b+ Ly6G+) in spleen 
(4.9% ± 0.5%; p < 0.05) and tumor microenvironment (TM) (1.1% ± 0.3%; p < 0.05) at 2 h, at approximately 2-fold 
and 4-fold lower respectively compared to the other three control groups. Comparing the two ligated conjugates 
in TM, YIYI-I2-BODIPY treated mice showed low G-MDSC population only at 24 h, whereas IYIY-I2-BODIPY 
treated group had low G-MDSC population at 2 h and remained low up to 24 h (Fig. 3a). Similarly, in the case of 
Treg cells, the population in IYIY-I2-BODIPY mice was found to decrease by approximately 1.4-fold in TDLN at 
24 h (p < 0.05) and 2-fold in TM at 24 h (p < 0.05) compared to mice treated with I2-BODIPY (Fig. 3b). Similar 
observations were made in experiments featuring YIYI-I2-BODIPY treated mice only at 24 h in TM. The decrease 
in Treg cells concurred with the depressed levels of the immunosuppressive cytokine TGF-β in both groups of 
ligands. Together, the data suggest that IYIY-I2-BODIPY was more rapid in reducing the populations of immuno-
suppressive G-MDSC and Treg compared to YIYI-I2-BODIPY, which was low only at the later time point (24 h) 
in TM.
Another subtype of myeloid cells, the neutrophils, was examined to confirm the suppressive activity of 
IYIY-I2-BODIPY on myeloid cell subsets. Neutrophils are defined by the expression of surface antigens CD11b 
and Ly6G, with the absence of the macrophage marker F4/8035. Similar to G-MDSC, the neutrophil population 
at 2 h was reduced. The reduction was 50% in spleen (p < 0.05) and 24% in TM (statistically insignificant) of 
IYIY-I2-BODIPY treated mice compared to mice treated with I2-BODIPY (Fig. 3c). In YIYI-I2-BODIPY treated 
mice, the neutrophil population was reduced by 13% at 2 h compared to mice treated with I2-BODIPY and at 24 h, 
the reduction was approximately 44% in spleen. As IL-6 is known to regulate MDSC expansion, our data suggests 
that the ligand-conjugates had direct impact on myeloid cells, rather than through IL-6 regulation.
IYIY-I2-BODIPY enhances T-lymphocytes population with IFN-γ (Th1, CTL) and IL-17 (Th17, 
Tc17) phenotype. Different T-lymphocyte subtypes secrete cytokines into systemic circulation, and these 
cytokines especially IL-2 can affect the differentiation, expansion and survival of T-lymphocytes via autocrine or 
paracrine systems36. Consequently, the impact of ligand-drug conjugates on T-lymphocyte subtypes populations 
was examined.
Populations of CD4+ T helper (Th) cell subsets and antigen specific CD8+ T cell subsets were determined 
in the tumor draining lymph node (TDLN) and tumor microenvironment (TM). Th1 cell populations (CD4+ 
IFN-γ +) in IYIY-I2-BODIPY treated mice were 2-fold higher in TDLN at 24 h and in TM at 2 h (p < 0.05), 
compared to mice treated with I2-BODIPY. In the YIYI-I2-BODIPY treated group, the Th1 subset was less 
at 24 h in both TDLN (1.7-fold) and TM (1.3-fold) compared to mice treated with I2-BODIPY (Fig. 4a). Th2 
(CD4+ IL-4+) populations in TDLN and TM were comparable among the treatment and control groups at 2 h. 
There was a moderate increase in TDLN at 24 h in IYIY-I2-BODIPY and YIYI-I2-BODIPY treated mice com-
pared to mice treated with I2-BODIPY and saline. Unlike TDLN, TM had lower Th2 populations in both 
IYIY-I2-BODIPY and YIYI-I2-BODIPY-treated mice at 24 h compared to mice treated with I2-BODIPY and saline 
(Supplementary Figure 2).
The Th17 cell population of IYIY-I2-BODIPY treated group was increased compared to mice treated with 
I2-BODIPY by 2.4- and 2.0-fold at 24 h in TDLN (p < 0.05) and TM respectively (Fig. 4b). This observation 
coincided with the moderate increase of the IL-17 secretion. Unlike Th1, the increase in Th17 cell was found 
to occur only in IYIY-I2-BODIPY treated group. This is similar for IL-6 level which was also only elevated in 
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IYIY-I2-BODIPY treated group, supporting that IL-6 selectively differentiates naive T cells to the Th17 subset. 
Taken together, the changes in Th population coincided well with the cytokines profiles in Fig. 2 and suggest that 
ligated conjugates increased Th1 and Th17 subsets of T cells population.
In addition, the CD8+ IFN-γ + T cell populations (Cytotoxic T Lymphocytes, CTL) was significantly increased 
in IYIY-I2-BODIPY treated mice (approximately 2 fold in TDLN at 24 h and in TM at 2 h; p < 0.05) compared 
to all treatment groups (Fig. 4c). For CD8+ IL17+ effector T cells (Tc17), the population in TDLN was almost 
comparable among the treatment and control groups. Unlike TDLN, TM has higher Tc17 populations in 
IYIY-I2-BODIPY treated mice at 24 h (7.3% ± 1.3%; p < 0.05) and for YIYI-I2-BODIPY-treated mice (approx-
imately 3.8%; p > 0.05) compared to mice treated with I2-BODIPY (1.3% ± 0.05%; Fig. 4d). This suggests that 
more effector T cells were generated following IYIY-I2-BODIPY administration compared to mice treated with 
I2-BODIPY, which then infiltrated to a high concentration at the TM (Fig. 4a–d). The elevation of effector T cells 
such as IFN-γ + and IL-17 + phenotypes is important for cytolytic activity and inflammation at tumor site.
Figure 3. Lymphoid organs and tumor microenvironment (TM) have lowered populations of myeloid 
cells and Treg cells in ligand-conjugates treated mice. 4T1 tumor bearing mice were randomly divided into 
four treatment groups (saline, I2-BODIPY, YIYI-I2-BODIPY and IYIY-I2-BODIPY) and compounds were 
administrated via tail vein respectively. Mice were then sacrificed at 2 h and 24 h post compound administration. 
At scheduled time points post compound administration, mice were sacrificed, followed by isolation of 
TDLN, spleen and tumor tissues. Immuno-phenotyping of (a) G-MDSC, (b) Treg and (c) neutrophil cells was 
conducted using surface staining of fluorescence conjugated antibodies and quantified using flow cytometry. 
Data represent mean ± SEM with minimum of four mice per group. *p < 0.05, ***p < 0.001 vs I2-BODIPY using 
one-way ANOVA (Dunnett’s test).
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Figure 4. IYIY-I2-BODIPY increases CD4+ and CD8+ T-lymphocytes expressing IFN-γ and IL-17. 4T1 
tumor bearing mice were randomly divided into four treatment groups (saline, I2-BODIPY, YIYI-I2-BODIPY 
and IYIY-I2-BODIPY) and compounds were administrated via tail vein respectively. Mice were then sacrificed 
at 2 h and 24 h post compound administration. TDLN and tumor tissues were isolated to generate single cells 
suspension. The suspension cells were activated using PMA/Ionomycin/golgi plug as described in Methods and 
Materials. Upon activation, CD4 marker was stained, followed by fixation and permeabilization for intracellular 
staining. (a) Th1 cells were stained with fluorescence conjugated anti-IFN-γ , (b) Th17 with anti-IL-17. CD8 
marker was stained, follow by intracellular staining with (c) anti-IFN-γ (CTL) and (d) anti-IL-17 (Tc17). Each 
group of cells was then quantified using flow cytometry. Data represent mean ± SEM with minimum of four 
mice per group. *p < 0.05 vs I2-BODIPY using One-way ANOVA (Dunnett’s test).
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7Scientific RepoRts | 6:37209 | DOI: 10.1038/srep37209
Immunomodulation properties of TrkC ligands were further confirmed when another control, IYIY-TEG 
(TrkC ligand without PS) reduced the immunosuppressive G-MDSC at 2 h and Treg cells (Fig. 5a), as well as 
increased Th17 (Fig. 5b), CTLs and Tc17 (Fig. 5c) at 24 h post administration, in the mice lymphoid organs. While 
no major changes were observed in the other parameters measured (G-MDSC at 24 h, Th1 cells and at 2 h time 
points of Th17 cells, CTLs and Tc17), these results largely mirror those produced by IYIY-I2-BODIPY. Based on 
this and the lack of immune activity from free I2-BODIPY as observed in Figs 2, 3 and 4, we propose that the fol-
lowing are direct effects of the IYIY ligand itself: (i) reduction of immunosuppressive mediators TGF-β , G-MDSC 
and Treg; and, (ii) elevation of adaptive immune responses with IFN-γ and IL-17 phenotypes. However, detailed 
mechanisms on how the ligands induced immune responses require further investigation.
TrkC blocking antibodies reverse the TrkC conjugates-mediated myeloid cell reduction. To 
address whether ligated conjugates induced immune modulations were TrkC dependent in vivo, an experiment 
to co-inject either TrkC polyclonal antibodies or isotype control Immunoglobulin-G (IgG) with IYIY-I2-BODIPY 
via tail vein was performed. Due to the high immunomodulation activity of IYIY-I2-BODIPY, it was selected to 
Figure 5. Control TrkC ligand (IYIY-TEG) has similar immunomodulatory activities as IYIY-I2-BODIPY. 
4T1 tumor bearing mice were administrated with IYIY-TEG via tail vein (equivalent dose to IYIY-I2-BODIPY) 
and mice were sacrificed at 2 h and 24 h post administration. Lymphoid organs were harvested and populations 
of (a) G-MDSCs and Treg cells (b) Th1 (CD4+ IFN-γ +), Th17 (CD4+ IL-17+) and (c) CTLs (CD8+ IFN-γ +), 
Tc17 (CD8+ IL-17+) cells were quantified using flow cytometry after labeling with fluorescence conjugated 
antibodies. Data represent mean ± SEM with minimum of four mice per group. *p < 0.05 vs saline control using 
student’s t-test.
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be co-administered with antibodies. Co-injection with 10 μ g/mouse of TrkC blocking antibodies reversed the 
IYIY-I2-BODIPY-mediated G-MDSC (p < 0.05) and neutrophil suppression (p < 0.05) in TM to levels similar to 
those in control saline, but this reversed activity was not observed to the same extent in the mice that received the 
isotype IgG control (Fig. 6). Reversal was not observed in the spleen G-MDSC and neutrophil levels, suggesting 
that the blocking effect of antibodies was local and not systemic. The reason of no reversal in spleen is unknown, 
but the overall result from the blocking experiment suggests that IYIY-I2-BODIPY mediated immunomodulation 
occurred in a TrkC dependent manner.
IYIY-I2-BODIPY promotes mild and transient delays in tumor growth. Up to now, we have shown 
that the ligated conjugates inhibited immuno-suppressive mediators and increased adaptive immune responses 
in breast tumor bearing mice. Next, we examined whether treatment with the conjugates caused delays in tumor 
growth in the dark. The experiment involved single bolus injections of 10 mg/kg of all three compounds via tail 
vein, and recording of tumor volume three times per week. The data shown in Fig. 7 was quantified in comparison 
to the initial volume of the respective tumors to eliminate tumor-to-tumor variation. As illustrated in Fig. 7a, 
single bolus injection had no effect on delaying tumor growth, as the tumor sizes were comparable with saline 
control in all treated groups. However, multiple injections of all three compounds with a regime of 10 mg/kg every 
day for five consecutive days resulted in marginal delay in tumor growth only after IYIY-I2-BODIPY adminis-
tration at the first three days following treatment (days 7–9 after tumor cells inoculation), and significant delay 
at days 10 (~16%) and 11 (~20%) post tumor cells injection compared to all controls (Fig. 7b). The growth delay 
was transient, as the tumor sizes became comparable when the administration of IYIY-I2-BODIPY was stopped. 
Even though the delay in tumor growth was statistically significant, the effect may not be strong or prolonged 
enough for clinical relevance. In addition, as only IYIY-I2-BODIPY but not YIYI-I2-BODIPY transiently delayed 
tumor growth, as well as elicited strong immune responses, our data suggest that tumor control was contributed 
by immune modulation.
Combination effect of conjugates and PDT in adaptive immunity. Adaptive immunity is highly 
specific to the antigens presented to the immune cells and generally provides long lasting protection to the host. 
In cancer, adaptive immune cells such as CD4+ T helper cells and CD8+ T cells are activated through presenta-
tion of tumor antigen in Major Histocompatibility Complex (MHC)-Class II and Class I by antigen presenting 
cells, respectively. Activated T-lymphocytes will undergo differentiation to various subtypes depending on the 
cytokines milieu present. In photodynamic therapy (PDT), antigen specific adaptive immune responses are acti-
vated by release of large quantities of tumor antigens by the damaged tumor tissues29,37.
Data obtained until this point suggest that the conjugate-ligands had immuno-stimulatory properties, hence 
we hypothesized that photo-activation of the I2-BODIPY photosensitizer counterpart of IYIY-I2-BODIPY 
and YIYI-I2-BODIPY (hereafter referred to as light treatment) following the administration of the conjugates 
into the mice may induce stronger adaptive immune responses. To explore this idea, tumor bearing mice were 
Figure 6. IYIY-I2-BODIPY mediated myeloid cells reduction is TrkC dependent. 4T1 tumor bearing mouse 
were randomly divided into four groups (saline, IYIY-I2-BODIPY, IYIY-I2-BODIPY + 10 μ g/mouse isotype 
control IgG, IYIY-I2-BODIPY + 10 μ g/mouse anti-TrkC blocking polyclonal antibodies). Compound, alone or 
in combination with antibodies as described was administrated into mice via tail vein, respectively. Mice were 
sacrificed 2 h after compounds administration. Percentages of (a) G-MDSCs and (b) neutrophils in spleen and 
TM were quantified using flow cytometry after cell surface staining. Data represent mean ± SEM of four mice. 
*p < 0.05 vs IYIY-I2-BODIPY was analyzed using student’s t-test.
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administrated with the IYIY-I2-BODIPY, YIYI-I2-BODIPY and I2-BODIPY (10 mg/kg equivalent dose) and illu-
minated with 100 J/cm2 of light after a drug-light interval of 1 h26. Mice were then sacrificed 2 h and 24 h after 
PDT.
Interestingly, most of the immune modulation responses observed in the dark for the ligated conjugates were 
also present in the light treatment. The data for IYIY-I2-BODIPY, YIYI-I2-BODIPY and I2-BODIPY-induced 
immune modulation following PDT are illustrated in Supplementary Figure 3 (systemic cytokines level) and 
Supplementary Figure 4 (immune cell populations in tumor microenvironment). For ease of comparison, the data 
for IYIY-I2-BODIPY (highest immunomodulatory activity) treated mice has been re-tabulated in terms of fold 
changes in the blood cytokines (Fig. 8a) and immune cell populations in tumor microenvironment (Fig. 8b) in 
light treatment compared to those in dark, at 2 and 24 h post-PDT treatment. Among the cytokines investigated, 
the biggest fold changes were: (i) 5.5-fold down-regulation of TGF-β and (ii) 13-fold up-regulation of IL-6, both 
at 24 h. High TGF-β suppression is similar to the previously reported effect of ligand-activated TrkC receptor 
in inhibiting TGF-β signaling21, whereas the elevation of IL-6 might be due to the effect of ligand in promot-
ing TrkC-induced IL-6 secretion17,18. IL-17A was 2.8-fold increased in the light compared to in the dark at 24 h 
post-PDT, further suggesting that the high IL-6 level induced by IYIY-I2-BODIPY had facilitated IL-17 + T-cell 
differentiation and IL-17 secretion. The rest of the cytokines investigated had fold changes ranging from 1.25 to 
2.4 (Fig. 8a).
For immune cell populations in the tumor microenvironment (Fig. 8b), Th2 cell population was reduced in 
the light at 2 h post-PDT compared to in the dark. The decrease of the Th2 cells post-PDT and increase of the 
Th1 cell population are in line with the known subtype balancing of Th1/Th2 cells, where activation of either cell 
type can down-regulate the other38. Unlike Th2, the other immune cell types investigated in IYIY-I2-BODIPY 
treated group were in increasing trend at 2 h and 24 h post-PDT compared to in the dark. The highest increase 
in fold change was observed in neutrophils (2.8-fold; Fig. 8b), suggesting that IYIY-I2-BODIPY recruited more 
neutrophils to TM post-light treatment.
Altogether, our data suggest that photoactivation of I2-BODIPY counterpart combined with the immune 
response of the IYIY ligand in the IYIY-I2-BODIPY conjugate to enhance levels of inflammatory cytokines IL-6 
and IL-17, T-lymphocyte with phenotype of IFN-γ + and IL-17+, and inflammatory cell neutrophils. This data 
may also explain the superior antitumor activity that was observed for PDT when using IYIY-I2-BODIPY with 
PDT26.
PDT increases effector T cells in IYIY-I2-BODIPY treated mice. Effective PDT of cancer would 
induce antitumor immunity through inflammation and adaptive immune responses39,40, which could further 
lead to the development of effector or memory T cells against the tumor29. Previously we have shown that 
71% of IYIY-I2-BODIPY treated mice were cured from tumor post PDT26. We sought to investigate whether 
IYIY-I2-BODIPY treated mice have increased CD4+ and CD8+ effector T-cell populations post PDT. Compounds 
treated mice underwent PDT and at 20 days post-PDT, TDLN and spleen were isolated and quantified for effector 
T cells using CD44 as a surface marker. As expected, IYIY-I2-BODIPY treated mice had significant high CD4+ 
(30.3 ± 1.8%, Fig. 9a) and CD8+ (12.4 ± 0.5%, Fig. 9b) effector T cells in TDLN compared to the other treatment 
and saline controls (~17–21% for CD4+, ~5–8% for CD8+), and only moderate increase in spleen (~13% CD4+; 
~7% CD8+) compared to other groups (~6–8% CD4+; 3–4% CD8+). However, no increase in effector T cells was 
Figure 7. Multiple boli i.v. administration of IYIY-I2-BODIPY delays tumor growth. At 7 days post 4T1 
inoculation, the mice were randomly divided into 4 groups. (a) For single bolus i.v. administration, the mice 
were injected with compounds (saline, I2-BODIPY, YIYI-I2-BODIPY and IYIY-I2-BODIPY) at dosages as 
shown. (b) For multiple boli i.v. administration, mice were injected with compounds at a regime of once a 
day for 5 days consecutively. Tumor growth was monitored and data represent mean percentage of initial 
volume ± SEM of n = 6. *p < 0.05 vs control saline, **p < 0.05 vs all three control groups using one-way ANOVA 
(Dunnett’s test).
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observed in YIYI-I2-BODIPY treated mice. This implies that IYIY-I2-BODIPY was a more effective PDT agent in 
inducing antitumor effector T cells than the YIYI conjugate.
Survivor mice ignite antitumor activity by delaying growth of aggressive 4T1 tumor. Lastly, 
we examined whether the IYIY-I2-BODIPY treated survivor mice post-PDT possess long term immunity against 
aggressive 4T1 tumor cells. In this study, IYIY-I2-BODIPY treated mice had high survival rate (60% of mice 
survived for up to 60 days), which was consistent with our previous study (71% of mice survived for up to 90 
days)26. The splenocytes and lymphocytes (suspension cells from TDLN) of healthy survivor mice were isolated 
and adoptively transferred into syngeneic healthy recipient mice via tail vein. Recipient mice were challenged by 
subcutaneous injection of 4T1 tumor cells at 2 days post adoptive transfer as described in Fig. 10a. Interestingly, 
tumor growth delay was observed in mice receiving splenocytes and lymphocytes from survivor mice, compared 
to controls (splenocytes and lymphocytes from healthy mice). In brief, the delay in tumor growth was transient 
at days one to four post tumor inoculation and became significant (~50%) in both splenocytes and lymphocytes 
recipient mice at 7 days post inoculation (p < 0.005, Fig. 10b). The delay in tumor growth continued, with approx-
imately 40% smaller tumors sizes in mice receiving immune cells from survivor mice at both 9 and 11 days post 
inoculation compared to mice with cells from healthy donors. Unfortunately, we failed to see full immunity in 
the mice after adoptive transfer, probably due to the highly aggressive and rapid proliferative nature of 4T1 tumor 
cells and failure in sorting of CD44+ T cells for adoptive transfer. However, the delayed tumor growth was signif-
icant as compared to controls, suggesting the presence of anti-tumor immune effector or memory T cells. Taken 
together, the higher survivor rate previously observed in IYIY-I2-BODIPY PDT treated mice compared to the 
Figure 8. IYIY-I2-BODIPY combined with PDT induces stronger adaptive immunity. 4T1 tumor bearing 
mice were treated with respective compounds via tail vain. Mice were kept in dark for 1 h, anaesthetized and 
irradiated with 100 J/cm2 of light at a fluence rate of 160 mW/cm2. Mice were then sacrificed at 2 h and 24 h 
post-PDT. Cytokines and immune cells quantification were examined based on the methods explained in 
M&M. Graph of fold changes in (a) blood cytokines and (b) immune cells populations in TM of the light 
(Supplementary Figure 3) versus dark (Figs 2, 3 and 4) for 2 h and 24 h in IYIY-I2-BODIPY treated group. Fold 
changes for each sample in IYIY-I2-BODIPY treated group was obtained by dividing the percentage in the light 
over the percentage in the dark. *p < 0.05, ***p < 0.001 vs IYIY-I2-BODIPY in the dark using student’s t-test.
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other controls26 might have been due to the enhanced effector or memory T cells caused by the combined TrkC 
and PDT therapy. A summary of results of IYIY-I2-BODIPY-mediated immune modulation is shown in Fig. 11.
Discussion
We examined the immunological impacts of a TrkC-targeted PDT agent upon compound administration in a 
TrkC + 4T1 breast tumor model. We observed that the TrkC targeted PDT conjugates in the dark transiently 
increased cytokines IL-2, IL-4, IL-6 and IL-17, and inhibited immunosuppressive mediators such as TGF-β 
cytokine, G-MDSC, Treg cells and inflammatory neutrophils. In addition, we found increases in the CD4+ and 
CD8+ antitumor responses with IFN-γ and IL-17 phenotypes, and growth delay of aggressive 4T1 tumors in 
mice. While IYIY-BODIPY in the dark activated mild immune reactions and decreased tumor growth to some 
extent, the assault by reactive oxygen species upon PDT accentuated those effects observed in dark. Upon PDT, 
the targeted conjugate-treated mice also had higher levels of IL-6, IL-17, CTL, effector T cells and lower level of 
TGF-β , as well as a delay in tumor growth through adoptive transfer of immune cells. In contrary to the dark, the 
level of neutrophils was enhanced in the conjugate PDT treated mice. To the best of our knowledge, this is the 
first report of antitumor immune responses elicited by a synthetic ligand designed primarily to actively directly a 
therapeutic agent to cancer.
Throughout the study, both in dark and light treatments, the scrambled control YIYI-I2-BODIPY showed 
similar, but weaker immune-modulation properties in Th1, CTL, TGF-β , Treg, MDSC than IYIY-I2-BODIPY. 
This might be due to the isomeric characteristics of scrambled ligands (reversed order of amino acids), leading to 
similar, albeit weaker binding affinity to the targeted receptor compared to the unscrambled ligands41. Another 
Figure 9. IYIY-I2-BODIPY treated mice have high CD4 + and CD8 + effector T cells in TDLN and spleen at 
20 days post-PDT. PDT was conducted at 100 J/cm2 based on four groups as indicated above. At 20 days post-
PDT, mice were sacrificed for quantification of (a) CD4+ and (b) CD8+ effector T cells in TDLN and spleen 
that expressed CD44 surface antigen using flow cytometry. Data represent mean ± SEM of three mice for each 
group. *p < 0.005; **p < 0.005 vs three control groups using one-way ANOVA (Dunnett’s test).
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Figure 10. Adoptive transfer of immune cells in IYIY-I2-BODIPY treated survivor mice delayed tumor 
growth. (a) The schematic diagram showed the work flow for antitumor immunity studies via adoptive transfer. 
(b) 4T1 tumor volume in four groups of mice is indicated above. Data represent mean ± SEM of 5 mice. 
*p < 0.05, **p < 0.005 vs respective control (healthy) using student’s t-test.
Figure 11. Summary of IYIY-I2-BODIPY mediated immune modulations in mouse 4T1 breast tumor 
model. 
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possibility is that the YIYI-I2-BODIPY scrambled control adopts a bioactive conformation that binds to other 
unknown receptors to also modulate immune response.
IYIY-I2-BODIPY induced IL-6 secretion and reduced G-MDSCs both in dark and light treatments. The 
increase of IL-6 by IYIY-I2-BODIPY was the same as other studies where neurotrophins binding to Trk receptor 
increased IL-6 secretion in bone marrow stromal cells17,18. The concurrent reduction in G-MDSCs however is 
in contrast as in other studies that reported correlative increases in IL-6 with MDSC expansion and inflamma-
tion31,32,42. It is possible that the TrkC ligand mediated MDSC suppression was independent of IL-6, but through 
direct binding to myeloid cells, since blocking with TrkC antibodies could reverse the IYIY-I2-BODIPY-mediated 
MDSC suppression. Another explanation for the mechanism of MDSC suppression may involve transcription 
factor STAT-3 which is an essential mediator for regulating myeloid progenitor proliferations43, as well as a down-
stream mediator of Trk signaling44.
Studies have revealed that the balance of Treg and Th17 differentiation is regulated by the relative abundance 
of differentiation factors TGF-β and IL-6. A high level of TGF-β generally promotes Treg differentiation and 
inhibits Th1745, whereas a high IL-6 level stimulates Th17 differentiation and antagonizes Treg formation46. Our 
findings on the increase of Th17 upon IYIY-I2-BODIPY administration both in dark and light treatments were 
in concordance with the latter scenario. Th17 cells secrete IL-17 cytokine that is known to possess both pro-
tumor and antitumor functions47. The IYIY-BODIPY mediated IL-17+ cells in this study probably functioned 
in an antitumor way based on (a) the observed delay in tumor growth post IYIY-I2-BODIPY administration, 
(b) the reduction of TGF-β which is known to block the production of vascular endothelial growth factor (VEGF, 
a potent angiogenic factor)48,49 and, (c) the increase in Th1 and CTL cell populations which have been reported 
in the presence of IL-1750,51.
TGF-β signaling has dual functions in cancer: (i) as a tumor suppressor to mediate growth arrest and apop-
tosis in cancer cells (antitumor)52,53, and (ii) as a potent immunosuppressive agent to suppress both innate and 
adaptive immune responses comprising of CD4+ effector T cells (Th1 and Th2), CD8+ cytotoxic T cells (CTLs), 
NK cells and antigen presenting cells, as well as to stimulate the generation of regulatory T cells which inhibit 
effector T cell functions (protumor)54. Jin and co-workers reported TrkC and its tyrosine kinase activity mediated 
tumorigenesis (protumor) through suppression of the tumor suppressor TGF-β signaling21, which is different 
from our study which showed conjugate-activated TrkC administered in dark inhibited TGF-β production and 
delayed tumorigenesis (antitumor). The discrepancy may be due to the dual function of TGF-β both as a pro- and 
an anti-tumor mediator54,55. To explain the antitumor role of TGF-β in our study, the binding of TrkC by the 
ligated conjugates might have activated the tyrosine kinase activity of TrkC and subsequently blocked the TGF-β 
signalling and inhibited TGF-β production at an early time point, which in turn reduced the Treg cells in a late 
time point to overall delay the tumor growth.
PDT can lead to systemic induction of IL-656,57, and this cytokine has been studied to possess dual func-
tions, either in enhancing PDT efficacy58,59 or inhibiting PDT mediated antitumor immunity60 via regulation of 
apoptotic proteins. Our PDT results in this study suggest that IL-6 was an antitumor factor, likely by enhancing 
PDT efficacy via upregulation of Th17 and Tc17 cells. This is contrary to the findings by Brackett et al.60, where 
they reported IL-6 attenuated PDT mediated antitumor immune memory in an IL-6 knockout mouse model 
implanted with 4T1 breast mammary tumor. The differences in findings might due to the different drugs admin-
istered (the ligand in our conjugate has additional immunomodulation properties) or the extreme difference in 
total systemic IL-6 level in different genetic background of mice (IL-6 knockout vs wild type). Overall, the role of 
IL-6 in PDT mediated immune responses may depend on the severity of inflammation and its action in mediating 
the balance between differentiation of Th17 and Treg cells.
IYIY-I2-BODIPY treated mice were shown here to increase recruitment of neutrophils to tumor tissues 
post-PDT, but this was not observed in both YIYI-I2-BODIPY and I2-BODIPY treated animals in both dark 
and light treatments. This can be explained by the good antitumor efficacy of IYIY-I2-BODIPY in causing tumor 
damage26, leading to the local accumulation of inflammatory cells such as neutrophils (Fig. 8b), as well as effector 
T cells (Fig. 9). This is concordant with de Vree et al.40, who proposed that high PDT efficacy is associated with 
increased population of neutrophils in systemic circulation.
In conclusion, stimulation of inflammatory IL-6, IL-17 cytokines and inhibition of immunosuppressive 
mediators are potential contributors of the immune stimulatory effects of the IYIY-ligand. This is different 
from other small molecules used in active targeting such as folate and estrogen which enhance the activity of 
immunoregulatory T cells - useful for treating autoimmune and inflammatory diseases61,62. In addition, the 
IYIY-I2-BODIPY conjugate has demonstrated potential as a therapeutic agent for cancer treatment by selectively 
destroying the TrkC + tumor cells in mice upon PDT with high post-treatment survival rate26, and at the same 
time stimulating antitumor immunity in the host. This suggests that TrkC targeted delivery, as demonstrated in 
the IYIY-I2-BODIPY conjugate can improve cancer treatment for patients. Further studies employing a modified 
BODIPY with an absorption maximum at higher wavelengths for deeper light penetration during therapeutic 
intervention are underway.
Materials and Methods
Compounds. TrkC targeted IYIY-I2-BODIPY (Isoleucine-Tyrosine-Isoleucine-Tyrosine, IYIY conjugated 
I2-BODIPY), non-TrkC targeted scrambled control YIYI-I2-BODIPY (Tyrosine-Isoleucine-Tyrosine-Isoleucine, 
YIYI conjugated I2-BODIPY), free photosensitizer I2-BODIPY and TrkC targeted ligand IYIY-TEG (Isoleucine-
Tyrosine-Isoleucine-Tyrosine conjugated to triethylene glycol (TEG) without I2-BODIPY) were synthesized as 
previously25.
Animal model. Female 8–10 week old, wild type BALB/c mice were purchased from Taconic and InVivos 
Pte Ltd, Singapore and maintained in the AAALAC accredited satellite animal facility at the Department of 
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Pharmacology, Faculty OF Medicine, University of Malaya. All animal experiments were performed according 
to protocols approved by the Faculty of Medicine Institutional Animal Care and Use Committee, University of 
Malaya (FOM IACUC). Ethics approval numbers: 2013-05-07/PHA/R/KLV and 20150303/PHAR/R/KCS.
Tumor model development. The fur of the BALB/C mouse was shaved and murine breast carcinoma 4T1 
cell line (ATCC) at a density of 5 × 105 cells in 0.1 mL of RPMI medium was orthotopically injected into the mam-
mary fat pad of the mice. The mice were monitored for tumor development every day and were then randomly 
divided into groups for compounds administration when the size reached around 60–80 mm3.
Compounds administration. IYIY-I2-BODIPY, YIYI-I2-BODIPY at 10 mg/kg of body weight (consist 
3.3 mg equivalent/kg of I2-BODIPY and 6.7 mg equivalent/kg of IYIY-TEG) and 3.3 mg/kg of I2-BODIPY were 
dissolved respectively in a cocktail of 2.5% ethanol and 2.5% CremophoreEL in saline. The mixture was then 
further dissolved using saline to a volume of 0.2 mL and intravenously administrated to tumor bearing mice via 
tail vein. The mice were then kept in an environment away from bright light for 2 h and 24 h (n = 5 per treatment 
group for every time point).
Blood sampling. At 2 h (represented innate immune response) and 24 h (represented onset of adaptive 
immune response) time points post compounds administration, mice from each group (n = 5 per time point) 
were anaesthetized with anaesthesia cocktail (90 mg/kg of ketamine and 10 mg/kg of xylazine). 0.5 mL of blood 
was withdrawn via cardiac puncture after the onset of anaesthesia.
Flow cytometry quantification of plasma cytokines. The withdrawn blood was centrifuged at 
5000 rpm for 10 minutes to separate the plasma and peripheral blood mononuclear cells. Cytokine levels in blood 
plasma were then determined using a BD Cytometric Bead Array (CBA) Mouse Th1/Th2/Th17 Cytokine Kit (BD 
Biosciences, San Jose, CA) according to manufacturer’s instructions. Cytokines IL-2, IL-4, IL-6, IFN-γ , TNF-α , 
IL-17A and IL-10 were quantified using FACSCanto II (BD Biosciences) and analysed using FCAP array software 
(BD Biosciences). TGF-β cytokine in blood plasma was quantified using Human/Mouse TGF-β 1 sandwich ELISA 
(eBiosciences, San Diego, CA) based on manufacturer’s instructions.
Cell isolation from lymphoid organs and tumor tissues. After the blood sampling at each indicated 
time points, mice (n = 5 per time point) were sacrificed and tumor draining lymph nodes (TDLN), spleen and 
tumor tissues were harvested. Single cell suspensions from TDLN and spleen were obtained by mincing the 
organs using frosted glass slides, followed by red blood cell lysis using red blood cell lysis buffer. Single cell 
suspensions from tumor tissues were obtained by mincing tumor tissue with frosted glass slides, followed by 
digestion with 0.5 mg/mL of collagenase type XI (Sigma Aldrich, St Louis, MO) for 30 minutes in a 37 oC shaker 
at 200 rpm. The cell suspensions were then filtered to eliminate the debris. All the single cell suspensions from 
TDLN and tumor tissues were stimulated for 4 h with 50 ng/mL of Phorbol 12-Myristate 13-Acetate (PMA), 
1 μ g/mL of Ionomycin (Sigma Aldrich, St Louis, MO) and 3 μ g/mL of brefeldin A (BD Bioscience, San Jose, CA)63.
Staining and flow cytometry quantification of immune cells. The stimulated single cell suspen-
sions from tumor tissues, TDLN and spleen were washed with PBS, and resuspended (1 × 106 cells) in FACS 
washing buffer (0.5% FBS and 0.05% sodium azide in PBS). The cells were then stained with a panel of fluoro-
chromes conjugated monoclonal antibodies purchased from BD Pharmingen to detect specific surface antigen 
that are FITC-anti mouse CD11b (553310), PE-anti mouse Ly6G (551461), APC-anti mouse F4/80 (17-4801), 
FITC-anti mouse CD4 (553729), PE-anti mouse CD25 (553075), FITC anti mouse CD8 (553031). The cells were 
fixed and permeabilized using Cytofix/Cytoperm kit (BD Biosciences, San Jose, CA) according to the manu-
facturer’s instructions. The surface antigens stained cells were then labelled for intracellular cytokine using 
PE-anti-mouse IFN-γ (554412), PerCP-Cy5.5-anti-mouse IL-4 (560700), APC-anti-mouse IL-17 (17-7177), and 
APC-anti-mouse FoxP3 (17-5773) with different fluorochrome combination to avoid overlap. We quantified the 
cells of interest based on surface markers, Th1 (CD4+ IFN-γ +), Th2 (CD4+ IL-4+), Th17 (CD4+ IL-17+), Treg 
(CD4+ CD25+ FoxP3+), CTL (CD8+ IFN-γ +), Tc-17 (CD8+ IL-17+), granulocytic-MDSC (CD11b+ Ly6G+, neu-
trophils (CD11b+ Ly6G+ F4/80−). Effector T cells were stained using PE-Cy5 rat anti-mouse CD44 (553135) for 
CD4+ CD44high and CD8+ CD44high populations. A total of 10,000 cells were analysed for every experiment. The 
stained cells was analysed in a FACS Canto-II Flow Cytometry (BD Biosciences, San Jose, CA). The data were 
analysed using Cell Quest software (BD Biosciences, San Jose, CA).
In vivo TrkC blocking studies. For TrkC blocking study, the tumor bearing mice (n = 4 per group) were 
treated with IYIY-I2-BODIPY (10 mg/kg) with or without mouse TrkC antibody (R&D systems, Minneapolis, 
MN) at a dosage of 10 μ g/mouse via tail vein and kept away from bright light as a non-irradiated study. Tumor 
bearing mice receiving isotype control Immunoglobulin G (R&D systems, Minneapolis, MN) at dosage of 10 μ g/
mouse (n = 4) was used as an antibody control in this study. At 2 h post IYIY-I2-BODIPY and antibodies admin-
istration, the mice were sacrificed and tumor tissues, spleen and TDLN were harvested, stained with respective 
fluorescence conjugates antibodies and phenotyped for granulocytic-MDSC, neutrophils, CD4+ and CD8+ T cell 
subtypes using flow cytometry.
Photodynamic therapy (PDT) in mice. For irradiation, IYIY-I2-BODIPY (10 mg/kg), YIYI-I2-BODIPY 
(10 mg/kg), I2-BODIPY (3.3 mg/kg) and saline were given respectively to the mice (n = 5 per group). The mice were 
kept away from bright light post compound administration for 1 h. Thereafter, anaesthesia cocktail of 90 mg/kg 
of ketamine and 10 mg/kg of xylazine was given to the mice. Upon the onset of anaesthesia, PDT was per-
formed using a Lumacare LC-122A fiber optic light delivery system (standard fiber optic probe model LUM 
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V, 400–700 nm, Lumacare Medical Group, Newport Beach, CA, USA, with a 500/585 nm bandpass filter from 
Omega Optical) to emit light at 530 nm. A 4 mm thick glass slide was used as a barrier to avoid direct photother-
mal effect on tumor. The illuminating spot was positioned at the tumor and the surrounding was covered using a 
black cloth to avoid PDT effect on non-tumor region of body. PDT was conducted at 100 J/cm2 with a fluence rate 
of 160 mW/cm2, for 10 minutes. The irradiated mice were then sacrificed for blood and lymphoid organ isolation 
at 2 h and 24 h post-PDT. The methods of samples processing in irradiated mice were same as methods described 
above (blood sampling, flow cytometry quantification of plasma cytokines, cell isolation from lymphoid organs 
and tumor tissues, staining and flow cytometry quantification of immune cells).
Adoptive transfer for antitumor immunity. For adoptive transfer studies, spleen and TDLN from 
healthy mice (n = 5) and the survivor mice (tumor free 60 days post PDT) in IYIY-I2-BODIPY treated group of 
mice (n = 5) were harvested. Splenocytes at a density of 2 × 107 cells/0.2 mL/mouse and lymphocytes from TDLN 
at a density of 1.5 × 107 cells/0.2 mL/mouse from each mouse were injected into different recipients of healthy 
syngeneic mice (n = 5) via the tail vein. After 2 days of adoptive transfer, the recipient mice were inoculated 
subcutaneously with 4T1 tumor cells at a density of 5 × 105 cells/0.1 mL/mouse. The tumor growth in the mice 
that received survivor splenocytes and lymphocytes was monitored and compared with the mice that received 
splenocytes and lymphocytes from the healthy mice.
Statistical analysis. The Student’s t-test and One-way ANOVA (Dunnett’s test) were used to determine 
the statistical differences between various experimental and control groups. A p value of < 0.05 was considered 
significant.
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